BOSTON, April 16, 2026 (GLOBE NEWSWIRE)-- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...
Teplizumab has shown significant preservation of C-peptide levels in newly diagnosed type 1 diabetes (T1D) patients, indicating the potential for modifying disease progression. Combining teplizumab ...
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated "brain fog”. BOSTON ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results